Biology

ALS and frontotemporal dementia: on a continuum or part of a spectrum of disorders?

A novel biomarker of Alzheimer’s disease progression: LTP-like cortical plasticity

Investigating physical activity and Alzheimer’s disease

Pioglitazone for the treatment of Alzheimer’s disease

Studying patients at risk of dementia and defining subjective cognitive decline

Basal forebrain atrophy and elevated plasmatic homocysteine levels

The effects of physical activity on Alzheimer’s disease biomarkers

Pilot study of polygenic risk score for Alzheimer’s disease

Investigating the reversal of cognitive decline in Alzheimer’s disease

Defining blood biomarkers to modify the diagnostic pathway of dementia

Clinical development of novel pharmacological treatments for Alzheimer’s disease

New approaches for developing disease modifying therapies in Alzheimer’s disease

Combination therapy for Alzheimer’s disease

Potential new symptomatic drugs for Alzheimer’s disease

Disease-modifying therapy for dementia: Challenges with early detection at pre-dementia stage

Ethical considerations of biomarker use in prodromal Alzheimer’s disease